Adicet Bio to Present at the 2023 JMP Securities Life Sciences Conference
09 Maio 2023 - 5:30PM
Business Wire
Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology
company discovering and developing allogeneic gamma delta T cell
therapies for cancer, today announced that Chen Schor, President
and Chief Executive Officer, will present at the 2023 JMP
Securities Life Sciences Conference being held from May 15-16, 2023
in New York.
Details of the event are as follows: Date: Tuesday, May 16, 2023
Time: 1:30 p.m. ET
The live audio webcast of the presentation can be accessed on
the Investors section of Adicet Bio’s website at
http://www.adicetbio.com. An archived replay will be available for
30 days following the presentation.
About Adicet Bio, Inc.
Adicet Bio, Inc. is a clinical stage biotechnology company
discovering and developing allogeneic gamma delta T cell therapies
for cancer. Adicet is advancing a pipeline of “off-the-shelf” gamma
delta T cells, engineered with chimeric antigen receptors (CARs)
and chimeric antigen adaptors (CAds), to enhance selective tumor
targeting and facilitate innate and adaptive anti-tumor immune
response for durable activity in patients. For more information,
please visit our website at https://www.adicetbio.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230509006078/en/
Adicet Bio., Inc. Investor and Media Contacts
Anne Bowdidge abowdidge@adicetbio.com
Janhavi Mohite Stern Investor Relations, Inc. 212-362-1200
janhavi.mohite@sternir.com
Adicet Bio (NASDAQ:ACET)
Gráfico Histórico do Ativo
De Abr 2024 até Mai 2024
Adicet Bio (NASDAQ:ACET)
Gráfico Histórico do Ativo
De Mai 2023 até Mai 2024